Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) shares dropped 4.3% during mid-day trading on Friday . The stock traded as low as $1.85 and last traded at $1.98. Approximately 62,019 shares were traded during trading, a decline of 44% from the average daily volume of 109,963 shares. The stock had previously closed at $2.07.
Cyclo Therapeutics Price Performance
The stock has a market cap of $16.79 million, a price-to-earnings ratio of -1.25 and a beta of -0.51. The company’s fifty day moving average price is $1.62 and its 200-day moving average price is $1.87.
Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) last posted its quarterly earnings data on Friday, November 11th. The company reported ($0.50) earnings per share (EPS) for the quarter. Cyclo Therapeutics had a negative net margin of 747.63% and a negative return on equity of 120.38%. The company had revenue of $0.45 million for the quarter.
Hedge Funds Weigh In On Cyclo Therapeutics
About Cyclo Therapeutics
Cyclo Therapeutics, Inc engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer’s disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
- Get a free copy of the StockNews.com research report on Cyclo Therapeutics (CYTH)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.